Cover Image
市場調查報告書

臨床前造影 (In-VIVO)的全球市場預測 2021年:光學影像,PET,SPECT,CT,MRI,超音波,光聲影像,磁性粒子影像 (MPI)

Preclinical Imaging (In-VIVO) Market by Modality (Optical Imaging, PET, SPECT, CT, MRI, Ultrasound, Photoacoustic Imaging, Magnetic Particle Imaging), Reagent - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 256349
出版日期 內容資訊 英文 165 Pages
訂單完成後即時交付
價格
Back to Top
臨床前造影 (In-VIVO)的全球市場預測 2021年:光學影像,PET,SPECT,CT,MRI,超音波,光聲影像,磁性粒子影像 (MPI) Preclinical Imaging (In-VIVO) Market by Modality (Optical Imaging, PET, SPECT, CT, MRI, Ultrasound, Photoacoustic Imaging, Magnetic Particle Imaging), Reagent - Global Forecast to 2021
出版日期: 2016年08月31日 內容資訊: 英文 165 Pages
簡介

全球臨床前造影市場,在預測期間內預計以6.2%的年複合成長率 (CAGR) 擴大,2021年達到9億1040萬美元的規模。分子影像技術的進步,及小動物影像技術的需求擴大,公私聯合的資金援助等,促進該市場的成長。再加上中國、印度、韓國、台灣等的新興國家市場正出現新的成長機會。另一方面,嚴格的法規和巨額的資本、運用費用等,妨礙市場成長。

本報告提供全球臨床前造影市場相關調查,各模式、試劑,及各地區的市場分析與預測,競爭環境分析,及主要企業簡介等彙整,為您概述為以下內容。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

第5章 臨床前造影 (In-VIVO)的全球市場:概要

  • 簡介
  • 市場動態
    • 推動因素
      • 在分子影像領域的技術進步
      • 低侵入性、小動物成像技術的市場需求擴大
      • 由於公私合營,前臨床試驗的支援策略、資金提供數量的增加
    • 阻礙因素
      • 對前臨床試驗的嚴格的法規
      • 有關臨床前造影模式的巨額設置、運用成本
    • 市場機會
      • 新興國家市場的新成長機會
    • 課題
      • 獨立式 (單獨型) 影像設備相關技術方面、治療方面的限制

第6章 臨床前造影 (In-VIVO)的全球市場:產業考察

  • 簡介
  • 價值鏈分析
  • 供應鏈分析
    • 主要的利害關係者(相關利益者)
    • 主要的影響要素
  • 主要產業趨勢
    • 現在進行中的混合/多模態臨床前造影系統
  • 波特的五力分析

第7章 臨床前造影 (In-VIVO)的全球市場:各種模式

  • 簡介
  • 光學影像系統
    • 生物冷光、螢光分子冷光影像系統
    • (光學+X光掃描)/(光學+CT) 影像系統
    • 獨立式螢光分子冷光影像系統
  • 核成像系統
    • 微PET系統
      • 獨立式PET系統
      • PET/CT系統
      • PET/MRI系統
    • 微SPECT系統
      • 獨立式SPECT系統
      • SPECT/CT系統
      • SPECT/MRI系統
    • 試模式 (SPECT/PET/CT) 系統
  • 微MRI系統
  • 微超音波設備
  • 微CT系統
  • 光聲影像系統
  • 磁性粒子影像 (MPI) 系統

第8章 臨床前造影 (In-VIVO)的全球市場:各試劑

  • 簡介
  • 前臨床光學影像試劑
    • 生物分子冷光影像試劑
      • luciferin
      • Proluciferin
      • Coelenterazine
      • 其他
    • 螢光分子冷光影像試劑
      • 綠色螢光蛋白
      • 紅色螢光蛋白質
      • 紅外線色素
      • 其他
  • 前臨床核成像試劑
    • 前臨床PET描繪器
      • 氟18類前臨床PET描繪器
      • 碳11類前臨床PET描繪器
      • 銅64類前臨床PET描繪器
      • 其他
    • 前臨床SPECT探針
      • 鎝99m類前臨床SPECT探針
      • 碘131類前臨床SPECT探針
      • 鎵67類前臨床SPECT探針
      • 鉈201類前臨床SPECT探針
      • 其他
  • 前臨床MRI顯影劑
    • 釓系前臨床顯影劑
    • 鐵型前臨床顯影劑
    • 錳系前臨床顯影劑
  • 前臨床超音波顯影劑
  • 前臨床CT顯影劑
    • 碘型前臨床CT顯影劑
    • 鋇系前臨床CT顯影劑
    • 黃金奈米粒子
    • GASTROGRAFIN系前臨床CT顯影劑

第9章 臨床前造影 (In-VIVO)的全球市場:各試劑

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他的國家 (RoW)

第10章 競爭環境

  • 概要
  • 市場佔有率分析:各主要企業
  • 競爭模式
    • 新產品的上市
    • 協定、產業聯盟、產業合作
    • 對全球各地的進出
    • 企業收購

第11章 企業簡介

  • 簡介
    • 地區間比較分析
  • PERKINELMER, INC.
  • BRUKER CORPORATION
  • FUJIFILM Holdings
  • MEDISO LTD.
  • MILABS B.V.
  • MR SOLUTIONS LTD.
  • ASPECT IMAGING LTD.
  • LI-COR BIOSCIENCES, INC.
  • TRIFOIL IMAGING, INC.
  • MILTENYI BIOTEC GMBH

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 3117

The global preclinical imaging market is estimated to grow at a high CAGR of 6.2% during 2016-2021; and is expected to be valued at USD 910.4 million by 2021. Although the mature markets (North America and Europe) held large share of preclinical imaging market in 2015; Asia-Pacific region is poised to be the fastest growing region during next five years. Factors such as continuous government support for pharmaceutical and biotechnology R&D, increasing public-private investments to support radioisotope production, rising number of translational research activities, and evolving regulatory scenario across major Asian countries are propelling the growth of the preclinical imaging market in Asia-Pacific region.

Market growth in the global preclinical imaging market is mainly driven by factors such technological advancements in the field of molecular imaging, increasing market demand for non-invasive small animal imaging techniques, and growing number of public-private initiatives and funding to support preclinical researches. In addition, emerging markets (such as China and India) are offering new growth opportunities for preclinical imaging market players.

Geographically, North America is estimated to command the largest share of the global preclinical imaging market in 2016, followed by Europe. The large market share of the North American region can be attributed to the robust R&D infrastructure for life science researches, fast adoption of novel molecular imaging technologies, significant presence of pharmaceutical and biotechnology companies, and increasing preference of end users for multimodality systems. However, continued outsourcing of in-house preclinical studies to emerging countries by U.S.-based pharmaceutical and biotechnology companies and reduced R&D expenditure by the Canadian government to support research studies are negatively affecting the growth of the preclinical imaging market in this region.

The preclinical imaging market is fairly competitive, with a large number of global and local manufacturers of preclinical imaging solutions. PerkinElmer, Inc. (U.S.), Bruker Corporation (U.S.), and FUJIFILM Holding Corporation (Japan) were the top three players in the preclinical imaging market in 2015. These companies together accounted for a share of 63.2% of the global preclinical imaging market in 2015. New product launches and product enhancements; geographic expansions; and partnerships, agreements, and collaborations are the major strategies adopted by most of the market players to achieve growth in the preclinical imaging market.

Report Objectives:

This report studies preclinical imaging market based on modality and reagents; utilized for the assessment of anatomical, physiological, and functional parameters at molecular and cellular levels in live animal models. These imaging systems and reagents are applied to visualize living animals during preclinical research studies in order to assess the safety and efficacy of novel drug procedures or other medical treatments for human applications.

The report also studies, the factors (such as drivers, restraints, opportunities, and challenges) which affect the market growth in positive and negative manner. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the preclinical imaging market report analyzes the micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market.

Detailed Segmentation:

Preclinical Imaging Market, by Modality:

  • Optical Imaging Systems
  • Bioluminescence/Fluorescence Imaging Systems
  • Standalone Fluorescence Imaging Systems
  • Optical + X-Ray/Optical + CT
  • Preclinical Nuclear Imaging Systems
  • Micro-PET Systems
  • Micro-SPECT Systems
  • Trimodality (SPECT/PET/CT) Systems
  • Micro-MRI Systems
  • Micro-Ultrasound Systems
  • Micro-CT Systems
  • Preclinical Photoacoustic Imaging Systems
  • Preclinical Magnetic Particle Imaging (MPI) Systems

Preclinical Imaging Market, by Reagents:

  • Preclinical Optical Imaging Reagents
  • Bioluminescent Imaging Reagents
  • Fluorescent Imaging Reagents
  • Preclinical Nuclear Imaging Reagents
  • Preclinical PET Tracers
  • Preclinical SPECT Probes
  • Preclinical MRI Contrast Agents
  • Gadolinium-based Preclinical MRI Contrast Agents
  • Iron-based Preclinical MRI Contrast Agents
  • Manganese-based Preclinical MRI Contrast Agents
  • Preclinical Ultrasound Contrast Agents
  • Preclinical CT Contrast Agents
  • Iodine-based Preclinical CT Contrast Agents
  • Barium-based Preclinical CT Contrast Agents
  • Gold Nanoparticles
  • Gastrografin-based Preclinical CT Contrast Agents

Preclinical Imaging Market, by Region:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Key Target Audience:

  • Preclinical Imaging Instrument Manufacturers, Suppliers, and Imaging Software Providers
  • Pharmaceutical and Biotechnology Companies
  • Preclinical Imaging Reagent Manufacturers and Suppliers
  • Contract Research Organizations (CROs)
  • Research and Development (R&D) Companies
  • Government Research Laboratories
  • Independent Research Laboratories
  • Government and Independent Regulatory Authorities
  • Market Research and Consulting Service Providers
  • Medical Research Laboratories
  • Academic Medical Institutes and Universities

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
      • 1.3.1.1. Preclinical imaging market segmentation
      • 1.3.1.2. Preclinical imaging systems market segmentation
      • 1.3.1.3. Preclinical imaging reagents market segmentation
    • 1.3.2. GEOGRAPHIC SCOPE
    • 1.3.3. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Breakdown of primaries
  • 2.2. MARKET SIZE ESTIMATION
      • 2.2.1.1. Bottom-up approach
      • 2.2.1.2. Top-down approach
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. RESEARCH ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL PRECLINICAL IMAGING MARKET
  • 4.2. PRECLINICAL IMAGING PRODUCTS MARKET SHARE, BY REGION (2016)
  • 4.3. GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET, BY MODALITY (2016-2021)
  • 4.4. GLOBAL PRECLINICAL IMAGING REAGENTS MARKET, BY TYPE (2016-2021)
  • 4.5. PRECLINICAL IMAGING MARKET, BY REGION (2016 VS. 2021)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. KEY MARKET DRIVERS
      • 5.2.1.1. Technological advancements in the field of molecular imaging
      • 5.2.1.2. Increasing market demand for noninvasive small-animal imaging techniques
      • 5.2.1.3. Growing number of public-private initiatives and funding to support preclinical researches
    • 5.2.2. KEY MARKET RESTRAINTS
      • 5.2.2.1. Strict regulations governing preclinical research
      • 5.2.2.2. Significant installation and operational costs associated with preclinical imaging modalities
    • 5.2.3. KEY MARKET OPPORTUNITY
      • 5.2.3.1. Emerging markets to offer new growth opportunities
    • 5.2.4. KEY MARKET CHALLENGE
      • 5.2.4.1. Technological and procedural limitations associated with standalone preclinical imaging systems

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. SUPPLY CHAIN ANALYSIS
    • 6.3.1. KEY STAKEHOLDERS
    • 6.3.2. KEY INFLUENCERS
  • 6.4. KEY INDUSTRY TREND
    • 6.4.1. ONGOING DEVELOPMENT OF HYBRID AND MULTI-MODALITY PRECLINICAL IMAGING SYSTEMS
  • 6.5. PORTER'S FIVE FORCES ANALYSIS
    • 6.5.1. THREAT OF NEW ENTRANTS
    • 6.5.2. THREAT OF SUBSTITUTES
    • 6.5.3. BARGAINING POWER OF SUPPLIERS
    • 6.5.4. BARGAINING POWER OF BUYERS
    • 6.5.5. INTENSITY OF COMPETITIVE RIVALRY

7. GLOBAL PRECLINICAL IMAGING MARKET, BY MODALITY

  • 7.1. INTRODUCTION
  • 7.2. OPTICAL IMAGING SYSTEMS
    • 7.2.1. BIOLUMINESCENCE AND FLUORESCENCE IMAGING SYSTEMS
    • 7.2.2. (OPTICAL + X-RAY)/(OPTICAL + CT) IMAGING SYSTEMS
    • 7.2.3. STANDALONE FLUORESCENCE IMAGING SYSTEMS
  • 7.3. NUCLEAR IMAGING SYSTEMS
    • 7.3.1. MICRO-PET SYSTEMS
      • 7.3.1.1. Standalone PET Systems
      • 7.3.1.2. PET/CT Systems
      • 7.3.1.3. PET/MRI Systems
    • 7.3.2. MICRO-SPECT SYSTEMS
      • 7.3.2.1. Standalone SPECT Systems
      • 7.3.2.2. SPECT/CT Systems
      • 7.3.2.3. SPECT/MRI Systems
    • 7.3.3. TRIMODALITY (SPECT/PET/CT) SYSTEMS
  • 7.4. MICRO-MRI SYSTEMS
  • 7.5. MICRO-ULTRASOUND SYSTEMS
  • 7.6. MICRO-CT SYSTEMS
  • 7.7. PHOTOACOUSTIC IMAGING SYSTEMS
  • 7.8. MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS

8. GLOBAL PRECLINICAL IMAGING MARKET, BY REAGENT

  • 8.1. INTRODUCTION
  • 8.2. PRECLINICAL OPTICAL IMAGING REAGENTS
    • 8.2.1. BIOLUMINESCENT IMAGING REAGENTS
      • 8.2.1.1. Luciferins
      • 8.2.1.2. Proluciferins
      • 8.2.1.3. Coelenterazine
      • 8.2.1.4. Other Bioluminescent Imaging Reagents
    • 8.2.2. FLUORESCENT IMAGING REAGENTS
      • 8.2.2.1. Green Fluorescent Proteins
      • 8.2.2.2. Red Fluorescent Proteins
      • 8.2.2.3. Infrared Dyes
      • 8.2.2.4. Other fluorescent imaging reagents
  • 8.3. PRECLINICAL NUCLEAR IMAGING REAGENTS
    • 8.3.1. PRECLINICAL PET TRACERS
      • 8.3.1.1. Fluorine-18-based Preclinical PET Tracers
      • 8.3.1.2. Carbon-11-based Preclinical PET Tracers
      • 8.3.1.3. Copper-64-based Preclinical PET Tracers
      • 8.3.1.4. Other PET tracers
    • 8.3.2. PRECLINICAL SPECT PROBES
      • 8.3.2.1. Technetium-99m-based Preclinical SPECT Probes
      • 8.3.2.2. Iodine-131-based Preclinical SPECT Probes
      • 8.3.2.3. Gallium-67-based Preclinical SPECT Probes
      • 8.3.2.4. Thallium-201-based Preclinical SPECT Probes
      • 8.3.2.5. Other SPECT probes
  • 8.4. PRECLINICAL MRI CONTRAST AGENTS
    • 8.4.1. GADOLINIUM-BASED PRECLINICAL CONTRAST AGENTS
    • 8.4.2. IRON-BASED PRECLINICAL CONTRAST AGENTS
    • 8.4.3. MANGANESE-BASED PRECLINICAL CONTRAST AGENTS
  • 8.5. PRECLINICAL ULTRASOUND CONTRAST AGENTS
  • 8.6. PRECLINICAL CT CONTRAST AGENTS
    • 8.6.1. IODINE-BASED PRECLINICAL CT CONTRAST AGENTS
    • 8.6.2. BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS
    • 8.6.3. GOLD NANOPARTICLES
    • 8.6.4. GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS

9. PRECLINICAL IMAGING MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
  • 9.3. EUROPE
  • 9.4. ASIA-PACIFIC
  • 9.5. REST OF THE WORLD (ROW)

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • 10.3. COMPETITIVE SCENARIO
    • 10.3.1. NEW PRODUCT LAUNCHES
    • 10.3.2. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 10.3.3. GEOGRAPHICAL EXPANSIONS
    • 10.3.4. ACQUISITIONS

11. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 11.1. INTRODUCTION
    • 11.1.1. GEOGRAPHIC BENCHMARKING
  • 11.2. PERKINELMER, INC.
  • 11.3. BRUKER CORPORATION
  • 11.4. FUJIFILM HOLDINGS CORPORATION
  • 11.5. MEDISO LTD.
  • 11.6. MILABS B.V.
  • 11.7. MR SOLUTIONS LTD.
  • 11.8. ASPECT IMAGING LTD.
  • 11.9. LI-COR BIOSCIENCES, INC.
  • 11.10. TRIFOIL IMAGING, INC.
  • 11.11. MILTENYI BIOTEC GMBH

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. INSIGHTS OF INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.5. AVAILABLE CUSTOMIZATIONS
  • 12.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2014-2021 (USD MILLION)
  • TABLE 2: GLOBAL OPTICAL IMAGING SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 3: OPTICAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: BIOLUMINESCENCE AND FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012-2014 (USD MILLION)
  • TABLE 5: (OPTICAL + X-RAY)/(OPTICAL + CT) IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012-2014 (USD MILLION)
  • TABLE 6: STANDALONE FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012-2014 (USD MILLION)
  • TABLE 7: GLOBAL NUCLEAR IMAGING SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 8: NUCLEAR IMAGING SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: GLOBAL MICRO-PET SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 10: MICRO-PET SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: STANDALONE PET SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: PET/CT SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: PET/MRI SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: GLOBAL MICRO-SPECT SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 15: MICRO-SPECT SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: STANDALONE SPECT SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: SPECT/CT SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: SPECT/MRI SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 19: TRIMODALITY SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: MICRO-MRI SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 21: MICRO-ULTRASOUND SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: MICRO-CT SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: PHOTOACOUSTIC IMAGING SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: MAGNETIC PARTICLE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 25: GLOBAL PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 26: GLOBAL PRECLINICAL OPTICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 27: PRECLINICAL OPTICAL IMAGING REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 28: GLOBAL PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 29: PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 30: PRECLINICAL LUCIFERINS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 31: PRECLINICAL PROLUCIFERINS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 32: PRECLINICAL COELENTERAZINE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 33: OTHER PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 34: GLOBAL PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 35: PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 36: PRECLINICAL GREEN FLUORESCENT PROTEINS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 37: PRECLINICAL RED FLUORESCENT PROTEINS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 38: PRECLINICAL INFRARED DYES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 39: OTHER PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 40: GLOBAL PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 41: PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 42: GLOBAL PRECLINICAL PET TRACERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 43: PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 44: FLUORINE-18-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 45: CARBON-11-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 46: COPPER-64-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 47: OTHER PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 48: GLOBAL PRECLINICAL SPECT PROBES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 49: PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 50: TECHNETIUM-99M-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 51: IODINE-131-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 52: GALLIUM-67-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 53: THALLIUM-201-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 54: OTHER PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 55: GLOBAL PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 56: PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 57: GADOLINIUM-BASED PRECLINICAL CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 58: IRON-BASED PRECLINICAL CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 59: MANGANESE-BASED PRECLINICAL CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 60: PRECLINICAL ULTRASOUND CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 61: GLOBAL PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 62: PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 63: IODINE-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 64: BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 65: GOLD NANOPARTICLES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 66: GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 67: GLOBAL PRECLINICAL IMAGING SYSTEMS AND REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 68: NORTH AMERICA: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 69: NORTH AMERICA: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2014-2021 (USD MILLION)
  • TABLE 70: NORTH AMERICA: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 71: EUROPE: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 72: EUROPE: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2014-2021 (USD MILLION)
  • TABLE 73: EUROPE: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 74: ASIA-PACIFIC: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 75: ASIA-PACIFIC: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2014-2021 (USD MILLION)
  • TABLE 76: ASIA-PACIFIC: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 77: ROW: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 78: ROW: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2014-2021 (USD MILLION)
  • TABLE 79: ROW: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 80: TOP NEW PRODUCT LAUNCHES, 2013-2016
  • TABLE 81: TOP AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2013-2016
  • TABLE 82: TOP GEOGRAPHICAL EXPANSIONS, 2013-2016
  • TABLE 83: TOP ACQUISITIONS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF SUPPLY-SIDE PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: PRECLINICAL IMAGING SYSTEMS MARKET: BOTTOM-UP APPROACH
  • FIGURE 4: PRECLINICAL IMAGING SYSTEMS MARKET: TOP-DOWN APPROACH
  • FIGURE 5: PRECLINICAL IMAGING REAGENTS MARKET: TOP-DOWN APPROACH
  • FIGURE 6: PRECLINICAL IMAGING MARKET: DATA TRIANGULATION
  • FIGURE 7: GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET, BY MODALITY, 2016 VS. 2021 (USD MILLION)
  • FIGURE 8: GLOBAL PRECLINICAL IMAGING REAGENTS MARKET, BY TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 9: GLOBAL PRECLINICAL IMAGING MARKET, BY REGION, 2016
  • FIGURE 10: TECHNOLOGICAL ADVANCEMENTS IN MOLECULAR IMAGING AND INCREASING DEMAND FOR NONINVASIVE TECHNIQUES-KEY MARKET DRIVERS
  • FIGURE 11: NORTH AMERICA IS EXPECTED TO DOMINATE THE PRECLINICAL IMAGING MARKET IN 2016
  • FIGURE 12: OPTICAL IMAGING, NUCLEAR IMAGING, AND MICRO-MRI SYSTEMS TO DOMINATE THE PRECLINICAL IMAGING SYSTEMS MARKET TILL 2021
  • FIGURE 13: OPTICAL IMAGING, NUCLEAR IMAGING REAGENTS AND MRI CONTRAST AGENTS TO DOMINATE THE REAGENTS MARKET TILL 2021
  • FIGURE 14: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE PRECLINICAL IMAGING MARKET IN 2016
  • FIGURE 15: TECHNOLOGICAL ADVANCEMENTS & EMERGING APPLICATION SEGMENTS TO DRIVE THE GROWTH OF THE PRECLINICAL IMAGING MARKET TILL 2021
  • FIGURE 16: HEALTHCARE EXPENDITURE ACROSS MAJOR COUNTRIES, 2000-2013
  • FIGURE 17: MAJORITY OF PRODUCT VALUE OF PRECLINICAL IMAGING SYSTEMS IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
  • FIGURE 18: MARKET PLAYERS PREFER BOTH DIRECT & INDIRECT DISTRIBUTION STRATEGIES
  • FIGURE 19: PORTER'S FIVE FORCES ANALYSIS: PRECLINICAL IMAGING MARKET (2015)
  • FIGURE 20: OPTICAL IMAGING SYSTEMS TO DOMINATE PRECLINICAL IMAGING SYSTEMS MARKET TILL 2021
  • FIGURE 21: OPTICAL IMAGING SYSTEMS MARKET TO BE DOMINATED BY BIOLUMINESCENCE AND FLUORESCENCE IMAGING SYSTEMS IN 2016
  • FIGURE 22: MICRO-PET SYSTEMS TO DOMINATE THE NUCLEAR IMAGING SYSTEMS MARKET TILL 2021
  • FIGURE 23: MAGNETIC PARTICLE IMAGING VS. OTHER PRECLINICAL IMAGING MODALITIES - ADVANTAGES AND KEY APPLICATION AREAS
  • FIGURE 24: OPTICAL IMAGING REAGENTS TO DOMINATE THE PRECLINICAL IMAGING REAGENTS MARKET TILL 2021
  • FIGURE 25: PRECLINICAL OPTICAL IMAGING REAGENTS MARKET, BY TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 26: PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET, BY TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 27: PRECLINICAL MRI CONTRAST AGENTS MARKET, BY TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 28: PRECLINICAL CT CONTRAST AGENTS MARKET, BY TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 29: ASIA-PACIFIC TO BE THE FASTEST-GROWING REGION IN GLOBAL PRECLINICAL IMAGING MARKET DURING THE FORECAST PERIOD
  • FIGURE 30: NORTH AMERICA: PRECLINICAL IMAGING MARKET SNAPSHOT (2016-2021)
  • FIGURE 31: EUROPE: PRECLINICAL IMAGING MARKET SNAPSHOT (2016-2021)
  • FIGURE 32: ASIA-PACIFIC: PRECLINICAL IMAGING MARKET SNAPSHOT (2016-2021)
  • FIGURE 33: ROW: PRECLINICAL IMAGING MARKET SNAPSHOT (2016-2021)
  • FIGURE 34: NEW PRODUCT LAUNCHES: KEY GROWTH STRATEGY ADOPTED BY MAJORITY OF MARKET PLAYERS (2013-2016)
  • FIGURE 35: GLOBAL PRECLINICAL IMAGING MARKET SHARE, BY KEY PLAYER (2015)
  • FIGURE 36: INCREASING NUMBER OF NEW PRODUCTS LAUNCHED IS STIMULATING THE MARKET GROWTH
  • FIGURE 37: GEOGRAPHIC REVENUE MIX OF THE TOP 3 MARKET PLAYERS (2015)
  • FIGURE 38: PERKINELMER, INC.: COMPANY SNAPSHOT
  • FIGURE 39: BRUKER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 40: FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT
Back to Top